Ishikawa N, Yagisawa T, Sakuma Y, Fujiwara T, Nukui A, Yashi M, Miyamoto N
Division of Renal Surgery and Transplantation, Department of Urology, Jichi Medical University School of Medicine, Tochigi, Japan.
Transplant Proc. 2008 Sep;40(7):2292-3. doi: 10.1016/j.transproceed.2008.06.024.
According to the Japanese renal transplant registry 2005, 834 transplantations were performed using living donors. Among them 199 (23.9%) kidneys were donated from spouses (husband/wife) and 174 (20.9%) from ABO-incompatible donors. This study summarized our experience of ABO-incompatible and living unrelated, especially spousal kidney transplantation.
We performed 44 cases of living donor kidney transplantation (LKT) between April 2003 and July 2007, including 14 (31.8%) from spouses (unrelated donor) who were divided into two groups: six patients (group 1; G1) from ABO-incompatible donors and eight patients (group 2; G2) from ABO-compatible donors. During the induction phase, tacrolimus or cyclosporine, mycophenolate mofetil, and methylprednisolone were used for immunosuppression. Basiliximab was administered on postoperative days 0 and 4. In all G1 patients plasmapheresis was performed to remove anti-AB antibodies prior to LKT, and splenectomy performed at the time of or before LKT.
Among G1, no patient died. Among G2, one patient died with a functioning graft due to a traumatic subdural hematoma. Graft survival rate was 100% in both groups. The incidence of acute rejection was 33.3% and 25.0% in G1 and G2, respectively. No patient experienced a lethal infectious complication.
Our results demonstrated that transplantation from an ABO-incompatible spousal donor was equivalent to transplantation from an ABO-compatible spousal donor. In response to the shortage of deceased donors, LKT between married couples and from ABO-incompatible donors will spread in Japan.
根据2005年日本肾移植登记处的数据,有834例肾移植使用了活体供体。其中199例(23.9%)肾脏由配偶(丈夫/妻子)捐赠,174例(20.9%)由ABO血型不相容的供体捐赠。本研究总结了我们在ABO血型不相容及活体非亲属,尤其是配偶肾移植方面的经验。
2003年4月至2007年7月期间,我们进行了44例活体供肾移植(LKT),其中14例(31.8%)来自配偶(非亲属供体),这些患者被分为两组:6例(第1组;G1)来自ABO血型不相容的供体,8例(第2组;G2)来自ABO血型相容的供体。在诱导期,使用他克莫司或环孢素、霉酚酸酯和甲泼尼龙进行免疫抑制。在术后第0天和第4天给予巴利昔单抗。所有G1组患者在LKT前进行血浆置换以去除抗AB抗体,并在LKT时或LKT前进行脾切除术。
在G1组中,无患者死亡。在G2组中,1例患者因外伤性硬膜下血肿死亡,移植肾仍有功能。两组的移植肾存活率均为100%。G1组和G2组的急性排斥反应发生率分别为33.3%和25.0%。无患者发生致命性感染并发症。
我们的结果表明,ABO血型不相容的配偶供体移植与ABO血型相容的配偶供体移植效果相当。鉴于已故供体短缺,已婚夫妇间及ABO血型不相容供体的LKT在日本将会增多。